Skip to main content
. 2017 Mar 31;143(8):1585–1596. doi: 10.1007/s00432-017-2402-x

Table 1.

Baseline demographics

Characteristics Young
(18–39 years)
(n = 243)
Middle age
(40–59 years)
(n = 494)
Elderly
(60–74 years)
(n = 300)
Old
(≥75 years)
(n = 52)
Median age (range), years 32 (18–39) 50 (40–59) 66 (60–74) 78 (75–91)
Male/female (%) 159/84 (34.6%) 286/208 (42.1%) 172/128 (42.7%) 25/27 (51.9%)
Time since initial diagnosis of CML (months); median (range) 0.86 (0.07, 5.86) 0.92 (0.07, 6.61) 0.92 (0.03, 60.99) 0.86 (0.07, 6.02)
Sokal score, n (%)
 High risk 31 (12.8) 84 (17.0) 71 (23.7) 11 (21.2)
 Intermediate risk 52 (21.4) 161 (32.6) 159 (53.0) 36 (69.2)
 Low risk 135 (55.6) 203 (41.1) 39 (13.0)
 Missing 25 (10.3) 46 (9.3) 31 (10.3) 5 (9.6)
EUTOS score, n (%)
 High risk 31 (12.8) 39 (7.9) 22 (7.3) 2 (3.8)
 Low risk 190 (78.2) 412 (83.4) 252 (84.0) 46 (88.5)
 Missing 22 (9.1) 43 (8.7) 26 (8.7) 4 (7.7)
Laboratory parameters
 Peripheral blasts %, mean ± SD (n) 2.05 ± 3.03 (230) 1.60 ± 2.33 (475) 1.49 ± 2.25 (283) 0.98 ± 1.04 (48)
 Peripheral eosinophils %, mean ± SD (n) 2.88 ± 3.37 (234) 2.73 ± 2.64 (479) 2.85 ± 3.14 (289) 2.47 ± 2.37 (49)
 Peripheral basophils %, mean ± SD (n) 4.02 ± 3.75 (234) 4.07 ± 3.83 (478) 4.08 ± 3.95 (292) 3.89 ± 3.72 (50)
 Platelets (109/L), mean ± SD (n) 446.47 ± 312.07 (240) 464.08 ± 352.63 (487) 463.28 ± 308.61 (297) 423.69 ± 233.39 (51)
 Spleen size, cm 5.01 ± 6.19 (226) 3.22 ± 4.90 (461) 2.46 ± 4.13 (276) 1.53 ± 3.06 (49)
Previous CML therapy, n (%)
 Imatinib ≤1 month 17 (7) 32 (6.5) 16 (5.3) 2 (3.8)
 Imatinib >1–2 months 13 (5.3) 33 (6.7) 24 (8.0) 1 (1.9)
 Imatinib >2–3 months 16 (6.6) 20 (4) 10 (3.3) 4 (7.7)

CML chronic myeloid leukemia, EUTOS European Treatment Outcome Study